Pages that link to "Q42168863"
Jump to navigation
Jump to search
The following pages link to Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors (Q42168863):
Displaying 50 items.
- Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean? (Q24630160) (← links)
- Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams (Q24631021) (← links)
- Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data (Q27009128) (← links)
- Pediatric Statin Administration: Navigating a Frontier with Limited Data (Q28068014) (← links)
- Managing dyslipidemia in HIV/AIDS patients: challenges and solutions (Q28084941) (← links)
- Rhabdomyolysis: pathogenesis, diagnosis, and treatment (Q28087634) (← links)
- Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register study (Q28535157) (← links)
- Quinine-induced renal failure as a result of rhabdomyolysis, haemolytic uraemic syndrome and disseminated intravascular coagulation (Q33371596) (← links)
- Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk (Q33617751) (← links)
- Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications (Q34099814) (← links)
- Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe. (Q34579515) (← links)
- Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. (Q34599850) (← links)
- General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs (Q34656231) (← links)
- Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin (Q34759583) (← links)
- Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin (Q34787395) (← links)
- Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition (Q34898182) (← links)
- Absence of a significant pharmacokinetic interaction between atorvastatin and fenofibrate: a randomized, crossover, study of a fixed-dose formulation in healthy Mexican subjects. (Q35025924) (← links)
- Gender differences, polypharmacy, and potential pharmacological interactions in the elderly. (Q35473198) (← links)
- Co-medication of statins with contraindicated drugs. (Q35561151) (← links)
- Risk assessment of mechanism-based inactivation in drug-drug interactions (Q36174265) (← links)
- A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death (Q36203546) (← links)
- Identification and Mechanistic Investigation of Drug-Drug Interactions Associated With Myopathy: A Translational Approach (Q36332525) (← links)
- Drug interactions during therapy with three major groups of antimicrobial agents (Q36429699) (← links)
- Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderly (Q36475343) (← links)
- Role of P-glycoprotein in statin drug interactions (Q36634221) (← links)
- Simvastatin: present and future perspectives (Q36916934) (← links)
- Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: a review. (Q36965617) (← links)
- A neuromuscular approach to statin-related myotoxicity. (Q37124768) (← links)
- Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy (Q37161532) (← links)
- Simvastatin: two decades in a circle (Q37165690) (← links)
- Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management (Q37414997) (← links)
- The effect of simvastatin on the proliferation and differentiation of human bone marrow stromal cells (Q37433910) (← links)
- Computing with evidence Part II: An evidential approach to predicting metabolic drug-drug interactions (Q37440022) (← links)
- Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network (Q37473382) (← links)
- Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers (Q37492042) (← links)
- Impact of cholesterol on ABC and SLC transporters expression and function and its role in disposition variability to lipid-lowering drugs (Q37521059) (← links)
- Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects (Q37631841) (← links)
- Does simvastatin cause more myotoxicity compared with other statins? (Q37634190) (← links)
- Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects (Q37680968) (← links)
- Atorvastatin: safety and tolerability (Q37765562) (← links)
- Clinical Importance of OATP1B1 and OATP1B3 in DrugDrug Interactions (Q37836255) (← links)
- Simvastatin interactions with other drugs (Q37993600) (← links)
- The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges (Q38024436) (← links)
- Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children (Q38049379) (← links)
- Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. (Q38075057) (← links)
- Drug interactions with statins (Q38155016) (← links)
- Cytochrome P450 and ischemic heart disease: current concepts and future directions (Q38166022) (← links)
- Genetics and personalized medicine--a role in statin therapy? (Q38167710) (← links)
- Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. (Q38284468) (← links)
- Drug-drug interactions that interfere with statin metabolism (Q38522299) (← links)